番茄社区app

Patients with complete response can have long treatment-free interval, study suggests

Other IKCS news: closer look at belzutifan safety, challenges of triplet therapies for RCC

Possible guidance for use of adjuvant immunotherapy in high-risk, non-metastatic disease

Better OS, PFS, response rate, but newer combination strategies not included

VA analysis finds men with limited life expectancy still getting aggressive treatment

More IKCS news: Long-term survival benefit with nivolumab/ipilimumab, disease-slowing surgery

Low rate of recurrence with surgery or nonsurgical options, but data can inform decisions

Confirmed responses in one-fourth to one-third of patients with refractory disease

And nearly half of responders to enfortumab vedotin plus pembrolizumab remained in remission

Researchers say inadequate understanding of risks may lead patients to regret treatment decisions

Health news and commentary gathered by 番茄社区app staff

Meta-analysis finds one most effective option to prevent symptomatic episodes

Study also raises question of antibiotic prophylaxis in kids with common congenital anomaly

New oral antibiotic gets a nod for uncomplicated urinary tract infections